Dimensional Fund Advisors LP Purchases 86,154 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

Dimensional Fund Advisors LP grew its position in Disc Medicine, Inc. (NASDAQ:IRON) by 160.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 139,720 shares of the company’s stock after acquiring an additional 86,154 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Disc Medicine were worth $8,856,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. FMR LLC raised its stake in shares of Disc Medicine by 358.7% in the 4th quarter. FMR LLC now owns 1,866,248 shares of the company’s stock valued at $118,320,000 after buying an additional 1,459,434 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Disc Medicine in the fourth quarter valued at about $5,579,000. Renaissance Technologies LLC acquired a new position in Disc Medicine in the fourth quarter worth about $5,479,000. JPMorgan Chase & Co. lifted its stake in Disc Medicine by 275.4% during the fourth quarter. JPMorgan Chase & Co. now owns 61,017 shares of the company’s stock worth $3,868,000 after purchasing an additional 44,762 shares during the period. Finally, Barclays PLC boosted its holdings in Disc Medicine by 123.7% during the third quarter. Barclays PLC now owns 40,145 shares of the company’s stock valued at $1,972,000 after purchasing an additional 22,202 shares in the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Trading Down 0.1 %

Shares of NASDAQ IRON opened at $44.24 on Friday. Disc Medicine, Inc. has a 1-year low of $30.65 and a 1-year high of $68.73. The company has a 50-day moving average of $46.93 and a two-hundred day moving average of $54.92. The company has a market cap of $1.53 billion, a PE ratio of -11.12 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.03). As a group, equities research analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on IRON shares. TD Cowen started coverage on Disc Medicine in a report on Thursday, February 27th. They issued a “buy” rating for the company. Stifel Nicolaus boosted their target price on shares of Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, January 24th. Morgan Stanley reiterated an “overweight” rating and set a $85.00 target price on shares of Disc Medicine in a research report on Friday, March 7th. Cantor Fitzgerald boosted their price target on shares of Disc Medicine from $99.00 to $132.00 and gave the company an “overweight” rating in a research report on Tuesday, March 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $118.00 price objective on shares of Disc Medicine in a report on Tuesday, January 21st. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $93.80.

Insider Transactions at Disc Medicine

In other Disc Medicine news, insider William Jacob Savage sold 2,100 shares of the business’s stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $50.17, for a total transaction of $105,357.00. Following the completion of the sale, the insider now directly owns 66,398 shares of the company’s stock, valued at approximately $3,331,187.66. The trade was a 3.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Mona Ashiya sold 202,146 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $54.29, for a total transaction of $10,974,506.34. Following the completion of the transaction, the director now directly owns 208,742 shares in the company, valued at $11,332,603.18. This trade represents a 49.20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 356,290 shares of company stock worth $19,336,901 over the last 90 days. 4.24% of the stock is owned by insiders.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.